Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-Term Follow Up in Anti-Contactin-1 Autoimmune Nodopathy.
Caballero-Ávila M, Martín-Aguilar L, Pascual-Goñi E, Michael MR, Koel-Simmelink MJA, Höftberger R, Wanschitz J, Alonso-Jiménez A, Armangué T, Baars AE, Carbayo Á, Castek B, Collet-Vidiella R, De Winter J, Del Real MÁ, Delmont E, Diamanti L, Doneddu PE, Hiew FL, Gallardo E, Gonzalez A, Grinzinger S, Horga A, Iglseder S, Jacobs BC, Jauregui A, Killestein J, Pozza EL, Martínez-Martínez L, Nobile-Orazio E, Ortiz N, Pérez-Pérez H, Poppert KN, Ripellino P, Roche JC, Rodriguez de Rivera FJ, Rostasy K, Sparasci D, Tejada-Illa C, Teunissen CCE, Vegezzi E, Xuclà-Ferrarons T, Zach F, Wieske L, Eftimov F, Lleixà C, Querol L. Caballero-Ávila M, et al. Among authors: horga a. Ann Neurol. 2024 Nov 27. doi: 10.1002/ana.27142. Online ahead of print. Ann Neurol. 2024. PMID: 39601182
Post-COVID symptoms of potential peripheral nervous and muscular origin.
Silva-Hernández L, Cabal-Paz B, Mayo-Canalejo D, Horga A. Silva-Hernández L, et al. Among authors: horga a. Neurol Perspect. 2021 Dec;1:S25-S30. doi: 10.1016/j.neurop.2021.11.002. Epub 2021 Dec 14. Neurol Perspect. 2021. PMID: 38620983 Free PMC article. Review.
Five-Year Results With Patisiran for Hereditary Transthyretin Amyloidosis With Polyneuropathy: A Randomized Clinical Trial With Open-Label Extension.
Adams D, Wixner J, Polydefkis M, Berk JL, Conceição IM, Dispenzieri A, Peltier A, Ueda M, Bender S, Capocelli K, Jay PY, Yureneva E, Obici L; patisiran Global OLE study group. Adams D, et al. JAMA Neurol. 2025 Jan 13. doi: 10.1001/jamaneurol.2024.4631. Online ahead of print. JAMA Neurol. 2025. PMID: 39804640
RTN2 deficiency results in an autosomal recessive distal motor neuropathy with lower limb spasticity.
Maroofian R, Sarraf P, O'Brien TJ, Kamel M, Cakar A, Elkhateeb N, Lau T, Patil SJ, Record CJ, Horga A, Essid M, Selim L, Benrhouma H, Ben Younes T, Zifarelli G, Pagnamenta AT, Bauer P, Khundadze M, Mirecki A, Kamel SM, Elmonem MA, Ghayoor Karimiani E, Jamshidi Y, Offiah AC, Rossor AM, Youssef-Turki IB, Hübner CA, Munot P, Reilly MM, Brown AEX, Nagy S, Houlden H. Maroofian R, et al. Among authors: horga a. Brain. 2024 Jul 5;147(7):2334-2343. doi: 10.1093/brain/awae091. Brain. 2024. PMID: 38527963 Free PMC article.
First-in-human trial evaluating safety and pharmacokinetics of AT-752, a novel nucleotide prodrug with pan-serotype activity against dengue virus.
Zhou X-J, Lickliter J, Montrond M, Ishak L, Pietropaolo K, James D, Belanger B, Horga A, Hammond J. Zhou X-J, et al. Among authors: horga a. Antimicrob Agents Chemother. 2024 May 2;68(5):e0161523. doi: 10.1128/aac.01615-23. Epub 2024 Mar 25. Antimicrob Agents Chemother. 2024. PMID: 38526047 Free PMC article. Clinical Trial.
Expanding the Clinical Spectrum of DRP2-Associated Charcot-Marie-Tooth Disease.
Sivera R, Pelayo-Negro AL, Jericó I, Domínguez-González C, Horga A, Rodriguez De Rivera FJ, Gallardo E, Tembl JI, Bermejo-Guerrero L, Pagola Lorz MI, Azorín I, Cordoba M, Fenollar-Cortés MDM, Millet E, Vilchez JJ, Espinós C, Apellániz-Ruiz M, Sevilla T. Sivera R, et al. Among authors: horga a. Neurology. 2024 Apr 9;102(7):e209174. doi: 10.1212/WNL.0000000000209174. Epub 2024 Mar 21. Neurology. 2024. PMID: 38513194
Oral bemnifosbuvir (AT-527) vs placebo in patients with mild-to-moderate COVID-19 in an outpatient setting (MORNINGSKY).
Horga A, Saenz R, Yilmaz G, Simón-Campos A, Pietropaolo K, Stubbings WJ, Collinson N, Ishak L, Zrinscak B, Belanger B, Granier C, Lin K, C Hurt A, Zhou XJ, Wildum S, Hammond J. Horga A, et al. Future Virol. 2023 Oct:10.2217/fvl-2023-0115. doi: 10.2217/fvl-2023-0115. Epub 2023 Nov 1. Future Virol. 2023. PMID: 37928891 Free PMC article.
A Phase 2 Randomized Trial Evaluating the Antiviral Activity and Safety of the Direct-Acting Antiviral Bemnifosbuvir in Ambulatory Patients with Mild or Moderate COVID-19 (MOONSONG Study).
Boffito M, Dolan E, Singh K, Holmes W, Wildum S, Horga A, Pietropaolo K, Zhou XJ, Clinch B, Collinson N, Ukachukwu V. Boffito M, et al. Among authors: horga a. Microbiol Spectr. 2023 Aug 17;11(4):e0007723. doi: 10.1128/spectrum.00077-23. Epub 2023 Jun 20. Microbiol Spectr. 2023. PMID: 37338393 Free PMC article. Clinical Trial.
68 results